Open access · US-GOV via ClinicalTrials.gov Clinical trial

CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

Authors not listed

Unlimited Biotechnology LLC · 2026

Dysbiosis Gene therapy Human Randomized controlled trial

Abstract

This Phase 1/2a, open-label, non-randomized study is designed to evaluate the safety and tolerability of intramuscular AAV9-Follistatin gene therapy administered either as monotherapy or in combination with a VEGF-encoding plasmid. Secondary objectives include the assessment of preliminary signals of biological and functional activity, including changes in skeletal muscle mass and performance.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-23 MST

Cite this

APA

Anonymous. (2026). CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy. <em>Unlimited Biotechnology LLC</em>. https://clinicaltrials.gov/study/NCT07443826

Vancouver

Anonymous. CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy. Unlimited Biotechnology LLC. 2026.

BibTeX

@misc{anon2026CALMAF, title = {CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy}, author = {Anonymous}, journal = {Unlimited Biotechnology LLC}, year = {2026}, }